TEHRAN, Jul. 19 (Press Shia) – Iran currently owns 20 out of 146 biotech drugs currently available in the global market, including four monoclonal antibody medicines and 16 recombinant drugs.
The list of the 20 biotech drugs produced in Iran includes: Erythropoietin alfa, Erythropoietin beta, G-CSF, Peg- G-CSF, Peg-INF alfa, INF gamma, INF alfa, INF beta- 1b, INF beta- 1a (30 micro gram), INF beta- 1a (44 micro gram), Factor VIII, Factor VII, Streptokinase, Teriparatide, FSH, Somatropin, Rituximab, Trastuzumab, Etanercept, Adalimumab.
These drugs are applicable in treatments of anemia, various types of cancer, chronic active hepatitis, severe osteoporosis, MS, hemophilia, infertility, arthritis, etc.
Secretary of the Department of Biotechnology Development, Dr. Mostaga Ghanei, told Mehr News correspondent that the production of 61 biotech drugs is on Iran’s national priority list, of which 29 drugs are currently at various stages of production by knowledge-based companies and will be ready to introduce to the market by a maximum of 5 years.
Ghanei maintained that Iran currently ranks fourth in the region in biotech drug production and will become the third in five years by completing the production of the mentioned 29 drugs.
These drugs include: Certolizumab pegol, Golimumab, Ustekinumab, Daclizumab, Infliximab, Vedolizumab, Pembrolizumab, Ipilimumab, Toclizumab, Ramucirumab, and 19 other drugs.